Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.
Hamimed M, Leblond P, Dumont A, Gattacceca F, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, André N, Ciccolini J. Hamimed M, et al. Among authors: de carli e. Cancer Chemother Pharmacol. 2022 Jul;90(1):29-44. doi: 10.1007/s00280-022-04446-y. Epub 2022 Jun 25. Cancer Chemother Pharmacol. 2022. PMID: 35751658 Clinical Trial.
VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Société Française des Cancers de l'Enfant (SFCE).
Bourdeaut F, de Carli E, Timsit S, Coze C, Chastagner P, Sarnacki S, Delattre O, Peuchmaur M, Rubie H, Michon J; Neuroblastoma Committee of the Société Française des Cancers et Leucémies de l'Enfant et de l'Adolescent. Bourdeaut F, et al. Among authors: de carli e. Pediatr Blood Cancer. 2009 May;52(5):585-90. doi: 10.1002/pbc.21912. Pediatr Blood Cancer. 2009. PMID: 19143025
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma.
Vairy S, Le Teuff G, Bautista F, De Carli E, Bertozzi AI, Pagnier A, Fouyssac F, Nysom K, Aerts I, Leblond P, Millot F, Berger C, Canale S, Paci A, Poinsignon V, Chevance A, Ezzalfani M, Vidaud D, Di Giannatale A, Hladun-Alvaro R, Petit FM, Vassal G, Geoerger B, Le Deley MC, Grill J. Vairy S, et al. Among authors: de carli e. Neurooncol Adv. 2020 Jun 9;2(1):vdaa075. doi: 10.1093/noajnl/vdaa075. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 32666050 Free PMC article.
Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.
Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Bernier-Chastagner V, Padovani L, Guerrini-Rousseau L, Faure-Conter C, Icher C, Bertozzi AI, Leblond P, Akbaraly T, Bourdeaut F, André N, Chappé C, Schneider P, De Carli E, Chastagner P, Berger C, Lejeune J, Soler C, Entz-Werlé N, Delisle MB. Dufour C, et al. Among authors: de carli e. Neuro Oncol. 2021 Jul 1;23(7):1163-1172. doi: 10.1093/neuonc/noaa301. Neuro Oncol. 2021. PMID: 33377141 Free PMC article. Clinical Trial.
What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?
Adelon J, Dufour C, Foulon S, Masliah Planchon J, Meyronnet D, Bourdeaut F, Palenzuela G, Fouyssac F, Raimbault S, De Carli E, Klein S, Pagnier A, Bertozzi AI, Rome A, David A, Chabaud S, Faure-Conter C. Adelon J, et al. Among authors: de carli e. J Neurooncol. 2021 Jul;153(3):425-440. doi: 10.1007/s11060-021-03777-9. Epub 2021 Jun 2. J Neurooncol. 2021. PMID: 34076831
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, Andre N, Aerts I, De Carli E, van Eijkelenburg N, Thebaud E, Corradini N, Defachelles AS, Ducassou S, Morscher RJ, Vassal G, Geoerger B. Bautista F, et al. Among authors: de carli e. J Clin Oncol. 2021 Nov 10;39(32):3546-3560. doi: 10.1200/JCO.21.01152. Epub 2021 Aug 4. J Clin Oncol. 2021. PMID: 34347542 Clinical Trial.
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Morscher RJ, Brard C, Berlanga P, Marshall LV, André N, Rubino J, Aerts I, De Carli E, Corradini N, Nebchi S, Paoletti X, Mortimer P, Lacroix L, Pierron G, Schleiermacher G, Vassal G, Geoerger B. Morscher RJ, et al. Among authors: de carli e. Eur J Cancer. 2021 Nov;157:268-277. doi: 10.1016/j.ejca.2021.08.010. Epub 2021 Sep 17. Eur J Cancer. 2021. PMID: 34543871 Clinical Trial.
Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma.
Hamimed M, Gattacceca F, André N, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, Leblond P. Hamimed M, et al. Among authors: de carli e. Br J Clin Pharmacol. 2022 May;88(5):2096-2117. doi: 10.1111/bcp.15131. Epub 2021 Dec 13. Br J Clin Pharmacol. 2022. PMID: 34709655 Free article. Clinical Trial.
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
de Marcellus C, Tauziède-Espariat A, Cuinet A, Pasqualini C, Robert MP, Beccaria K, Puget S, Boddaert N, Figarella-Branger D, De Carli E, Bourdeaut F, Leblond P, Fouyssac F, Andre N, Bertozzi AI, Butel T, Dufour C, Valteau-Couanet D, Varlet P, Grill J. de Marcellus C, et al. Among authors: de carli e. J Neurooncol. 2022 Apr;157(2):355-364. doi: 10.1007/s11060-022-03970-4. Epub 2022 Mar 3. J Neurooncol. 2022. PMID: 35239111
57 results